{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:20:30Z","timestamp":1775809230936,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00105-020-04738-5","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T02:28:32Z","timestamp":1607480912000},"page":"729-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Zostererkrankung nach Shingrix-Impfung","Zoster disease after Shingrix vaccination"],"prefix":"10.1007","volume":"72","author":[{"given":"D.","family":"Kohn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Wetzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"issue":"8","key":"4738_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1080\/21645515.2017.1317410","volume":"13","author":"T Bharucha","year":"2017","unstructured":"Bharucha\u00a0T, Ming\u00a0D, Breuer\u00a0J (2017) A critical appraisal of \u201cShingrix\u201d, an novel herpes zoster subunit vaccine (HZ\/Su or GSK 1437173A) for varicella zoster virus. Hum Vaccin Immunother 13(8):1789\u20131797","journal-title":"Hum Vaccin Immunother"},{"key":"4738_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","volume":"59","author":"TC Heineman","year":"2019","unstructured":"Heineman\u00a0TC, Cunningham\u00a0A, Levin\u00a0M (2019) Understanding the immunology of Shingrix, a\u00a0recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr Opin Immunol 59:42\u201348","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"4738_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","volume":"68","author":"EM Hesse","year":"2019","unstructured":"Hesse\u00a0EM et\u00a0al (2019) Postlicensure safety surveillance of recombinant zoster vaccine (Shingrix)\u2014Unites States, October 2017\u2013June 2018. MMWR Morb Mortal Wkly Rep 68(4):91\u201394","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"4738_CR4","first-page":"e4920","volume":"11","author":"M Heydari-Kamjani","year":"2019","unstructured":"Heydari-Kamjani\u00a0M, Vante\u00a0I, Uppal\u00a0P et al (2019) Uveitis sarcoidosis presumably initiated after administration of Shingrix vaccine. Cureus 11(6):e4920","journal-title":"Cureus"},{"key":"4738_CR5","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1016\/j.vaccine.2019.03.043","volume":"37","author":"M L\u00f3pez-Fauqued","year":"2019","unstructured":"L\u00f3pez-Fauqued\u00a0M et al (2019) Safety profile oft he adjuvanted recombinant zoster vaccine: poled analysis oft wo large randomises phase 3 trials. Vaccine 37:2482\u20132493","journal-title":"Vaccine"},{"key":"4738_CR6","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40266-018-0603-x","volume":"35","author":"YY Syed","year":"2018","unstructured":"Syed\u00a0YY (2018) Recombinant zoster vaccine (Shingrix): a review in herpes zoster. Drugs Aging 35:1031\u20131040","journal-title":"Drugs Aging"},{"key":"4738_CR7","series-title":"Drug Safety Mail","volume-title":"Fallberichte von Herpes zoster nach Shingrix-Impfung","author":"Arzneimittelkommission der deutschen \u00c4rzteschaft","year":"2019","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft (2019) Fallberichte von Herpes zoster nach Shingrix-Impfung. Drug Safety Mail, Bd. 2019\u201346"},{"key":"4738_CR8","volume-title":"Shingrix","author":"GlaxoSmithKline GmbH & Co. KG","year":"2019","unstructured":"GlaxoSmithKline GmbH & Co. KG (2019) Shingrix"},{"key":"4738_CR9","volume-title":"Faktenbl\u00e4tter zum Impfen","author":"Robert Koch Institut","year":"2019","unstructured":"Robert Koch Institut (2019) Faktenbl\u00e4tter zum Impfen"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04738-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-020-04738-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04738-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T07:04:19Z","timestamp":1627542259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-020-04738-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4738"],"URL":"https:\/\/doi.org\/10.1007\/s00105-020-04738-5","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,8]]},"assertion":[{"value":"18 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Kohn und T.\u00a0Wetzig geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}